Mesothelioma | Mesothelioma

SNS-595 acts selectively through DNA-PK signaling in the S-phase of the cell cycle to kill proliferating cancer cells by inducing apoptosis, or programmed cell death.

SNS-032 is in a Phase I/II clinical studies to examine the safety and preliminary anti-tumor activity among patients with lung cancer, breast cancer or melanoma.

SNS-032 is a potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9.

Sunesis is currently conducting preclinical studies of its Aurora kinase inhibitor drug candidate, SNS-314.

In addition, in cooperation with Biogen Idec, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases.About Sunesis PharmaceuticalsSunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases.

Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics.

Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies.Forward-Looking StatementsThis press release may contain forward-looking statements that involve substantial risks and uncertainties...

Read more...